Navigation Links
Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
Date:6/12/2008

or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form SB-2, as amended, that was declared effective on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on April 15, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

The Ruth Group

Sara Ephraim (investors) Janine McCargo (media)

(646) 536-7002 (646) 536-7033

sephraim@theruthgroup.com jmcc
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... LEXINGTON, Ky. (PRWEB) March 03, 2015 ... aligning their schedules for one event: the Alltech REBELation ... USA, from May 17-20. Now in its 31st year, ... people from 70 countries, and the opportunity to join ... week, March 7 at 11:59 p.m. EST, at which ...
(Date:3/3/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Chief Executive Officer of Neurocrine Biosciences, will be presenting ... The live presentation takes place on Tuesday, ... will be webcast and may be accessed on the ... Listeners are encouraged to visit the website approximately 5 ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 ... Inc. to their international sales network. The business ... dissolution technology to Canada’s Atlantic Provinces, exclusively through ... served as one of Canada’s premiere manufacturing representative ... both the municipal water and wastewater markets. More ...
(Date:3/3/2015)... YORK , March 3, 2015 Fried, ... Jeffrey I.D. Lewis has joined the Firm ... resident in the New York ... handles trademark matters, as well as other intellectual property ... patent attorney, Mr. Lewis represents both plaintiffs and defendants ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3
... (OTC Bulletin Board: CCEL) (the "Company"), one of ... banks, today,announced results for the second quarter and ... revenues for the second quarter were approximately $4.5,million, ... for the second quarter of 2007. The Company ...
... Guidance: (greater than or equal,to)12%, EUR millions 2006 ... EURM %Sales EURM %Sales % EURM %Sales ... change ... 13 26.8 71 15 Other EU countries (2) 6.9 24 7.7 ...
... /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology,International, Inc. ("Yongye" or ... distributor of plant and animal nutrients headquartered ... MSPC Certified Public,Accountants and Advisors, P.C. as ... has engaged MSPC Certified Public Accountants and ...
Cached Biology Technology:Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 2Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 3Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 4Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 5Cryo-Cell International, Inc. Reports Second Quarter 2008 Results 6Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2Yongye Biotechnology International, Inc. Appoints New Independent Auditor 2
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... 2012) When different types of cells are transplanted ... central nervous system (CNS) trauma, what is the fate ... carried out research aimed at answering this question by ... cells, mouse embryonic fibroblasts, dendritic cells, bone marrow mononuclear ...
... been recognized for creating technologies or processes that can ... fight cancer and detect explosives, and then moving the ... announced today that the Department of Energy national laboratory ... Transfer awards. The consortium is a nationwide network ...
... (WCS) lauded U.S. Secretary of the Interior Ken Salazars ... Petroleum Reserve-Alaska (NPR-A) that balances wildlife conservation and energy ... The Integrated Activity Plan and Final Environmental Impact ... Land Management is the first comprehensive land management plan ...
Cached Biology News:Cell Transplantation study investigates fate and function of cells transplanted to the CNS 2PNNL recognized for transferring innovations to the marketplace 2PNNL recognized for transferring innovations to the marketplace 3WCS applauds Dept. of Interior plan balancing conservation and energy development in NPR-A 2
... for Alkaline Phosphatase conjugates. The product ... both the enzyme and the antibody following ... product has been chemically engineered to increase ... shelf life, resistance to various shipping conditions ...
... Protein Microarray Slide features an ultra-thin ... Slide is the first protein microarray ... of nitrocellulose in a thin film ... ratios. ,The PATH™ Slide can ...
... Cassettes facilitate the hybridization of DNA or ... 25mm x 75mm glass slides. The proprietary ... correct for poor flatness, as is often ... low volume chamber (67uL analytical cavity volume) ...
... Lambda Free Light Chain ... of human immunoglobulin. Specificity: ... epitope of lambda chain. Reacts with ... lambda chains but not with lambda ...
Biology Products: